Oncolytics Biotech (NASDAQ:ONCY) Releases Earnings Results, Beats Estimates By $0.01 EPS

Oncolytics Biotech (NASDAQ:ONCY) issued its earnings results on Friday. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01, Zacks reports.

Oncolytics Biotech Stock Down 6.8 %

ONCY traded down $0.05 during trading on Friday, hitting $0.69. 107,413 shares of the company traded hands, compared to its average volume of 1,395,583. Oncolytics Biotech has a one year low of $0.60 and a one year high of $1.53. The stock’s fifty day moving average is $0.79 and its 200 day moving average is $0.94. The firm has a market cap of $58.57 million, a P/E ratio of -2.54 and a beta of 1.18.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Leede Financial downgraded shares of Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a report on Wednesday, November 13th. Raymond James raised shares of Oncolytics Biotech to a “moderate buy” rating in a research report on Thursday, November 14th. Finally, HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of Oncolytics Biotech in a research note on Monday, February 3rd.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.